Kulkarni Santosh S, Kopajtic Theresa A, Katz Jonathan L, Newman Amy Hauck
Medicinal Chemistry Section, Intramural Research Program, National Institute on Drug Abuse, NIH, 5500, Nathan Shock Drive, Baltimore, MD 21224, USA.
Bioorg Med Chem. 2006 Jun 1;14(11):3625-34. doi: 10.1016/j.bmc.2006.01.017. Epub 2006 Feb 3.
Benztropine (BZT) and its analogues inhibit dopamine uptake and bind with moderate to high affinity to the dopamine transporter (DAT). However, many of these compounds, in contrast to other monoamine uptake inhibitors, lack cocaine-like behavioral effects and fail to potentiate the effects of cocaine. The BZT analogues also exhibit varied binding affinities for muscarinic M(1) and histamine H(1) receptors. In this study, a comparative analysis was conducted of pharmacophoric features with respect to the activities of BZT analogues at the DAT and at the histamine H(1) receptor. The BZT analogues showed a wide range of histamine H(1) receptor (K(i)=16-37,600 nM) and DAT (K(i)=8.5-6370 nM) binding affinities. A stereoselective histamine H(1)-antagonist pharmacophore, using a five-point superimposition of classical antagonists on the template, cyproheptadine, was developed. A series of superimpositions and comparisons were performed with various analogues of BZT. In general, smaller substituents were well tolerated on the aromatic rings of the diphenyl methoxy group for both the DAT and H(1) receptor, however, for the H(1) receptor, substitution at only one of the aromatic rings was preferred. The substituents at the 2- and N-positions of the tropane ring were preferred for DAT, however, these groups seem to overlap receptor essential regions in the histamine H(1) receptor. Molecular models at the DAT and the histamine H(1) receptor provide further insight into the structural requirements for binding affinity and selectivity that can be implemented in future drug design.
苯海索(BZT)及其类似物可抑制多巴胺摄取,并以中等到高亲和力与多巴胺转运体(DAT)结合。然而,与其他单胺摄取抑制剂不同的是,这些化合物中的许多都缺乏可卡因样行为效应,且无法增强可卡因的作用。BZT类似物对毒蕈碱M(1)和组胺H(1)受体也表现出不同的结合亲和力。在本研究中,针对BZT类似物在DAT和组胺H(1)受体上的活性,对药效团特征进行了比较分析。BZT类似物显示出广泛的组胺H(1)受体(K(i)=16 - 37,600 nM)和DAT(K(i)=8.5 - 6370 nM)结合亲和力。利用经典拮抗剂与模板赛庚啶的五点叠加,开发了一种立体选择性组胺H(1) - 拮抗剂药效团。对BZT的各种类似物进行了一系列叠加和比较。总体而言,对于DAT和H(1)受体,二苯甲氧基的芳环上较小的取代基耐受性良好,然而,对于H(1)受体,仅在一个芳环上进行取代是优选的。托烷环2位和N位的取代基对DAT是优选的,然而,这些基团似乎与组胺H(1)受体中的受体关键区域重叠。DAT和组胺H(1)受体的分子模型为未来药物设计中可实现的结合亲和力和选择性的结构要求提供了进一步的见解。